Parkinson Disease: all 4,583 studies

Page 16 of 46. Open to participants first (1,097), then studies with results posted, then the rest; newest registration first within each.

• The Cyclical Lower-extremity Exercise for Parkinson's TrialCompletedNCT01636297Not applicableResults posted
• Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor FluctuationsTerminatedNCT01634360Phase 2Results posted
• A Dose-ranging Study for SPM 962 in Parkinson's Disease PatientsCompletedNCT01634243Phase 2Results posted
• A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease PatientsCompletedNCT01631825Phase 3Results posted
• A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease PatientsCompletedNCT01631812Phase 2Results posted
• A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease PatientsCompletedNCT01628965Phase 2/3Results posted
• A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease PatientsCompletedNCT01628926Phase 3Results posted
• A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease PatientsCompletedNCT01628848Phase 2Results posted
• Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s DiseaseCompletedNCT01606670Results posted
• A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric EmptyingCompletedNCT01602549Phase 2Results posted
• Tango for Treatment of Motor and Non-motor Manifestations in Parkinson's Disease.CompletedNCT01573260Early Phase 1Results posted
• Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" PhenomenonCompletedNCT01568073Phase 3Results posted
• Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) PatientsCompletedNCT01568047Phase 2Results posted
• A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067CompletedNCT01568034Phase 2Results posted
• Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty AcidsCompletedNCT01563913Phase 1Results posted
• Tandem DBS for Parkinson's Disease: A Pilot Study Utilizing STN/GPi + Hypothalamic StimulationCompletedNCT01563341Not applicableResults posted
• Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in ChinaCompletedNCT01556165Phase 3Results posted
• Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease ProgressionCompletedNCT01556100Phase 2Results posted
• A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's DiseaseCompletedNCT01539837Phase 2Results posted
• Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528CompletedNCT01536574Phase 3Results posted
• Effect of BIA 9-1067 on the Pharmacokinetics of RepaglinideCompletedNCT01536366Phase 1Results posted
• Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal DysfunctionTerminatedNCT01536015Phase 3Results posted
• Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/BenserazideCompletedNCT01533116Phase 1Results posted
• Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/CarbidopaCompletedNCT01533077Phase 1Results posted
• Randomized Trial to Test the "Coordinated Care for Health Promotion and Activities in Parkinson's Disease" Intervention in the VACompletedNCT01532986Not applicableResults posted
• Effect of Rasagiline on BIA 9-1067 PharmacokineticsCompletedNCT01532141Phase 1Results posted
• Effect of BIA 9-1067 on Rasagiline PharmacokineticsCompletedNCT01532128Phase 1Results posted
• PharmacoMRI of Parkinson DiseaseCompletedNCT01528592Not applicableResults posted
• Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's DiseaseCompletedNCT01525641Results posted
• Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease PatientsCompletedNCT01523301Phase 4Results posted
• The Effect of Donepezil on Gait and Balance in Parkinson's DiseaseCompletedNCT01521117Phase 4Results posted
• Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian SubjectsCompletedNCT01520987Phase 1Results posted
• A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male SubjectsCompletedNCT01520727Phase 1Results posted
• Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's DiseaseTerminatedNCT01519882Phase 4Results posted
• Study of BIA 9-1067 to Investigate Its Effect on Levodopa PharmacokineticCompletedNCT01519284Phase 1Results posted
• Mild Cognitive Impairment in Parkinson's DiseaseCompletedNCT01519271Phase 4Results posted
• An Open-label Safety Study of Pimavanserin in Parkinson's Disease PatientsCompletedNCT01518309Phase 2Results posted
• Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and MetabolitesCompletedNCT01515891Phase 1Results posted
• Study in Advanced Parkinson's Disease Patients With Predictable Motor FluctuationsCompletedNCT01515410Phase 2Results posted
• Study in Parkinson's Disease of ExerciseCompletedNCT01506479Not applicableResults posted
• A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's DiseaseCompletedNCT01494532Phase 4Results posted
• A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's DiseaseCompletedNCT01491022Phase 1/2Results posted
• A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's DiseaseCompletedNCT01485172Phase 4Results posted
• Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in ChinaCompletedNCT01479530Phase 3Results posted
• Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's DiseaseCompletedNCT01479127Phase 2Results posted
• The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's DiseaseCompletedNCT01470859Not applicableResults posted
• N-Acetylcysteine for Neuroprotection in Parkinson's DiseaseCompletedNCT01470027Phase 1/2Results posted
• Apolipoprotein D (ApoD) In Human Serum As Marker Of Parkinson's DiseaseStatus unknownNCT01467960Results posted
• The Effects of Sertraline on Depression in Parkinson's DiseaseCompletedNCT01437189Not applicableResults posted
• Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's DiseaseCompletedNCT01427517Phase 1Results posted
• Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's DiseaseCompletedNCT01421719Phase 4Results posted
• Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety StudyCompletedNCT01411137Phase 3Results posted
• High and Low Dose Carbidopa Treatment of Parkinson's DiseaseCompletedNCT01399905Phase 2Results posted
• Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)CompletedNCT01397422Phase 2/3Results posted
• Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.CompletedNCT01380899Results posted
• A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's DiseaseCompletedNCT01370811Phase 2Results posted
• a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease PatientsCompletedNCT01361009Results posted
• Acupuncture for Fatigue in Parkinson's DiseaseCompletedNCT01360229Not applicableResults posted
• Varenicline for Gait and Balance Impairment in Parkinson DiseaseCompletedNCT01341080Phase 2Results posted
• Cognitive Decline in Non-demented PDCompletedNCT01340885Phase 4Results posted
• Light Therapy Treatment in Parkinson's Disease Patients With Daytime SomnolenceCompletedNCT01338649Not applicableResults posted
• Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver SupportCompletedNCT01330290Results posted
• A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)CompletedNCT01323855Phase 1Results posted
• Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor SymptomsCompletedNCT01300819Phase 4Results posted
• A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)CompletedNCT01294800Phase 2Results posted
• Pioglitazone in Early Parkinson's DiseaseCompletedNCT01280123Phase 2Results posted
• Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)CompletedNCT01270711Results posted
• Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in KoreaCompletedNCT01268891Phase 3Results posted
• Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's DiseaseTerminatedNCT01227681Phase 2Results posted
• Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.CompletedNCT01227655Phase 3Results posted
• Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)CompletedNCT01227265Phase 3Results posted
• Vercise Implantable Stimulator for Treating Parkinson's DiseaseCompletedNCT01221948Phase 2Results posted
• An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)TerminatedNCT01215227Phase 3Results posted
• Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) PatientsCompletedNCT01191944Phase 3Results posted
• A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's DiseaseCompletedNCT01176240Phase 3Results posted
• A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease PsychosisCompletedNCT01174004Phase 3Results posted
• Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's DiseaseCompletedNCT01168596Phase 4Results posted
• Barriers to Mental Healthcare Utilization in Parkinson's DiseaseCompletedNCT01167608Results posted
• Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal PatchCompletedNCT01159691Results posted
• Exercise and Cognitive Training in Parkinson's DiseaseCompletedNCT01156714Not applicableResults posted
• A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)TerminatedNCT01155479Phase 3Results posted
• A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)CompletedNCT01155466Phase 3Results posted
• A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-DopaCompletedNCT01154166Phase 3Results posted
• Swallowing Training in Parkinson's DiseaseCompletedNCT01131494Not applicableResults posted
• A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066CompletedNCT01130493Phase 3Results posted
• Effects of Vitamin D in Parkinson's Disease (PD)CompletedNCT01119131Phase 2Results posted
• Imaging Biomarkers of Progression of Mobility Impairment in Parkinson DiseaseCompletedNCT01106976Results posted
• Transcranial Direct Current Stimulation (tDCS) and Parkinson's DiseaseCompletedNCT01100762Not applicableResults posted
• Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of LifeCompletedNCT01100073Results posted
• Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s DiseaseCompletedNCT01097421Results posted
• An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's DiseaseCompletedNCT01096186Phase 3Results posted
• Cognitive Rehabilitation in Parkinson's DiseaseCompletedNCT01085968Early Phase 1Results posted
• rTMS for Motor and Mood Symptoms of Parkinson's DiseaseCompletedNCT01080794Not applicableResults posted
• Phase II Subthalamic Nucleus (STN) vs. Globus Pallidus (GPi) TrialCompletedNCT01076452Phase 3Results posted
• Validation of Dyskinesia Rating ScalesCompletedNCT01071395Phase 4Results posted
• Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical PracticeCompletedNCT01061567Results posted
• The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary EventsCompletedNCT01052948Results posted
• Naltrexone for Impulse Control Disorders in Parkinson's DiseaseCompletedNCT01052831Phase 4Results posted
• Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's DiseaseCompletedNCT01049984Phase 4Results posted
• Follow Up Study for Treatment of Parkinson's Disease With Deep Brain StimulationCompletedNCT01022073Results posted

← Parkinson Disease overview